Risk stratification in extranodal natural killer/T-cell lymphoma

References

• Liang X, Graham DK. Natural killer cell neoplasms. Cancer112(7), 1425–1436 (2008).
   PubMed Web of Science ®Google Scholar
• Chan J, Quintanilla-Martinez L, Ferry J, Peh S. World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissues. Jaffe E, Harris N, Stein H, Vardiman J (Eds). IARC Press, Lyon, France (2008).
   Google Scholar
• Au WY, Ma SY, Chim CS et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann. Oncol.16(2), 206–214 (2005).
   PubMed Web of Science ®Google Scholar
• Suzuki R, Nakamura S, Suzumiya J et al. Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer104(5), 1022–1031 (2005).
   PubMed Web of Science ®Google Scholar
• Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood113(17), 3931–3937 (2008).
   PubMedGoogle Scholar
• Robbins KT, Fuller LM, Vlasak M et al. Primary lymphomas of the nasal cavity and paranasal sinuses. Cancer56(4), 814–819 (1985).
   PubMed Web of Science ®Google Scholar
• Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk. Lymphoma49(11), 2099–2107 (2008).
   PubMed Web of Science ®Google Scholar
• Lee J, Park YH, Kim WS et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur. J. Cancer41(10), 1402–1408 (2005).
   PubMed Web of Science ®Google Scholar
• Kwong YL, Chan AC, Liang RH. Natural killer cell lymphoma/leukemia: pathology and treatment. Hematol. Oncol.15(2), 71–79 (1997).
   PubMed Web of Science ®Google Scholar
• Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia19(12), 2186–2194 (2005).
   PubMed Web of Science ®Google Scholar
• Weiss LM, Movahed LA. In situ demonstration of Epstein–Barr viral genomes in viral-associated B cell lymphoproliferations. Am. J. Pathol.134(3), 651–659 (1989).
   PubMed Web of Science ®Google Scholar
• Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection. Annu. Rev. Immunol.15, 405–431 (1997).
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Huh J et al. Effect of positive bone marrow EBV In situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. Clin. Cancer Res.13(11), 3250–3254 (2007).
   PubMed Web of Science ®Google Scholar
• Oshimi K, Kawa K, Nakamura S et al. NK-cell neoplasms in Japan. Hematology10(3), 237–245 (2005).
   PubMed Web of Science ®Google Scholar
• Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood113(17), 3931–3937 (2009).
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J. Clin. Oncol.24(4), 612–618 (2006).
   PubMed Web of Science ®Google Scholar
• Huang M-j, Jiang Y, Liu W-p et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int. J. Radiat. Oncol. Biol. Phys.70(1), 166–174 (2008).
   PubMed Web of Science ®Google Scholar
• Li CC, Tien HF, Tang JL et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer100(2), 366–375 (2004).
   PubMed Web of Science ®Google Scholar
• Kim GE, Lee SW, Chang SK et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother. Oncol.61(3), 261–269 (2001).
   PubMed Web of Science ®Google Scholar
• Kako S, Izutsu K, Ota Y et al. FDG-PET in T-cell and NK-cell neoplasms. Ann. Oncol.18(10), 1685–1690 (2007).
   PubMed Web of Science ®Google Scholar
• Khong PL, Pang CB, Liang R, Kwong YL, Au WY. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann. Hematol.87(8), 613–621 (2008).
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int. J. Radiat. Oncol. Biol. Phys.54(1), 182–190 (2002).
   PubMed Web of Science ®Google Scholar
• Kim TM, Park YH, Lee SY et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood106(12), 3785–3790 (2005).
   PubMed Web of Science ®Google Scholar
• Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood103(1), 216–221 (2004).
   PubMed Web of Science ®Google Scholar
• Guo Y, Lu JJ, Ma X et al. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Oral Oncol.44(1), 23–30 (2008).
   PubMed Web of Science ®Google Scholar
• Aviles A, Diaz NR, Neri N, Cleto S, Talavera A. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin. Lab. Haematol.22(4), 215–220 (2000).
   PubMedGoogle Scholar
• Kim SJ, Kim BS, Choi CW et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann. Oncol.18(8), 1382–1387 (2007).
   PubMed Web of Science ®Google Scholar
• Chiang AK, Wong KY, Liang AC, Srivastava G. Comparative analysis of Epstein–Barr virus gene polymorphisms in nasal T/NK-cell lymphomas and normal nasal tissues: implications on virus strain selection in malignancy. Int. J. Cancer80(3), 356–364 (1999).
   PubMed Web of Science ®Google Scholar
• Nagamine M, Takahara M, Kishibe K et al. Sequence variations of Epstein–Barr virus LMP1 gene in nasal NK/T-cell lymphoma. Virus Genes34(1), 47–54 (2007).
   PubMed Web of Science ®Google Scholar
• Suzumiya J, Ohshima K, Takeshita M et al. Nasal lymphomas in Japan: a high prevalence of Epstein–Barr virus type A and deletion within the latent membrane protein gene. Leuk. Lymphoma35(5–6), 567–578 (1999).
   PubMed Web of Science ®Google Scholar
• Wang J, Hasui K, Jia X, Matsuyama T, Eizuru Y. Possible role for external environmental stimuli in nasopharyngeal NK/T-cell lymphomas in the northeast of China with EBV infection-related autophagic cell death: a pathoepidemiological analysis. J. Clin. Exp. Hematop.49(2), 97–108 (2009).
   PubMedGoogle Scholar
• Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood104(1), 243–249 (2004).
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim KH, Chang MH et al. Whole blood Epstein–Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk. Lymphoma50(5), 757–763 (2009).
   PubMed Web of Science ®Google Scholar
• You JY, Chi KH, Yang MH et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann. Oncol.15(4), 618–625 (2004).
   PubMed Web of Science ®Google Scholar
• Kim TM, Lee SY, Jeon YK et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann. Oncol.19(8), 1477–1484 (2008).
   PubMed Web of Science ®Google Scholar
• Lee J, Kim WS, Park YH et al. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br. J. Cancer92(7), 1226–1230 (2005).
   PubMed Web of Science ®Google Scholar
• Isobe K, Uno T, Tamaru J et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer106(3), 609–615 (2006).
   PubMed Web of Science ®Google Scholar
• Kim K, Chie EK, Kim CW, Kim IH, Park CI. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J. Clin. Oncol.35(1), 1–5 (2005).
   PubMed Web of Science ®Google Scholar
• Li YX, Yao B, Jin J et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J. Clin. Oncol.24(1), 181–189 (2006).
   PubMed Web of Science ®Google Scholar
• Li YX, Fang H, Liu QF et al. Clinical features and treatment outcome of nasal-type NK/T cell lymphoma of Waldeyer’s ring. Blood112(8), 3057–3064 (2008).
   PubMed Web of Science ®Google Scholar
• Kwong YL. High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant.44(11), 709–714 (2009).
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhang Y. Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma. Zhonghua Yi Xue Za Zhi81(13), 773–775 (2001).
   PubMedGoogle Scholar
• Kim BS, Kim TY, Kim CW et al. Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy – result of chemotherapy in NK/T-cell lymphoma. Acta Oncol.42(7), 779–783 (2003).
   PubMed Web of Science ®Google Scholar
• Lee KW, Yun T, Kim DW et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk. Lymphoma47(7), 1274–1282 (2006).
   PubMed Web of Science ®Google Scholar
• Liang R, Todd D, Chan TK et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J. Clin. Oncol.13(3), 666–670 (1995).
   PubMed Web of Science ®Google Scholar
• Li YX, Coucke PA, Li JY et al. Primary non-Hodgkin’s lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer83(3), 449–456 (1998).
   PubMed Web of Science ®Google Scholar
• Kim GE, Cho JH, Yang WI et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J. Clin. Oncol.18(1), 54–63 (2000).
   PubMed Web of Science ®Google Scholar
• Au W, Intragumtornchai T, Nakamura S, Armitage JO, Liang R. Clinical and pathological differences between nasal and nasal-type NK/T cell lymphomas: a summary of 136 cases from the International T Cell Lymphoma (ITCL) Project. ASH Annual Meeting Abstracts108(11), 292 (2006).
   Google Scholar
• Kim SJ, Kim K, Kim BS et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study. J. Clin. Oncol.27(35), 6027–6032 (2009).
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: final results of JCOG0211. J. Clin. Oncol. (Meeting Abstracts)27(15S), 8549 (2009).
   Google Scholar
• Yamaguchi M, Oguchi M, Tobinai K et al. Phase I/II study of concurrent chemoradiotherapy for newly-diagnosed, localized nasal NK/T-cell lymphoma: results of a Phase I portion of JCOG0211-DI. ASH Annual Meeting Abstracts106(11), 2685 (2005).
   Google Scholar
• Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol.10(11), 1093–1101 (2009).
   PubMed Web of Science ®Google Scholar
• Kwong YL, Chan AC, Liang R et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br. J. Haematol.97(4), 821–829 (1997).
   PubMed Web of Science ®Google Scholar
• Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood80(11), 2735–2739 (1992).
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kenkichi K, Hiroshi M et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer76(11), 2351–2356 (1995).
   PubMed Web of Science ®Google Scholar
• Wang B, Li XQ, Ma X, Hong X, Lu H, Guo Y. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am. J. Hematol.83(10), 795–799 (2008).
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Fernandez R, Calva A, Huerta-Guzman J, Nambo MJ. Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med. Oncol.20(1), 13–17 (2003).
   PubMed Web of Science ®Google Scholar
• Aviles A, Cleto S, Castaneda C, Nambo MJ. CMED in the treatment of nasal natural killer cell lymphoma with distant metastases. Hematology12(3), 241–244 (2007).
   PubMed Web of Science ®Google Scholar
• Ando M, Sugimoto K, Kitoh T et al. Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br. J. Haematol.130(6), 860–868 (2005).
   PubMed Web of Science ®Google Scholar
• Reyes VE Jr, Al-Saleem T, Robu VG, Smith MR. Extranodal NK/T-cell lymphoma nasal type: efficacy of pegaspargase. Report of two patients from the United Sates and review of literature. Leuk. Res.34(1), e50–e54 (2010).
   PubMedGoogle Scholar
• Jaccard A, Petit B, Girault S et al.L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann. Oncol.20(1), 110–116 (2009).
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhu J et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol. Oncol.24(1), 28–32 (2006).
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Coppo P et al. A prospective Phase II trial of an L-asparaginase containing regimen in patients with refractory or relapsing extra nodal NK/T-cell lymphoma. ASH Annual Meeting Abstracts112(11), 579 (2008).
   Google Scholar
• Yamaguchi M, Suzuki R, Kwong YL et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci.99(5), 1016–1020 (2008).
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong Y, Maeda Y et al. Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: NKTSG study. J. Clin. Oncol. (Meeting Abstracts)28(15s), 8044 (2010).
   Google Scholar
• Au WY, Lie AK, Liang R et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann. Oncol.14(11), 1673–1676 (2003).
   PubMed Web of Science ®Google Scholar
• Suzuki R, Suzumiya J, Nakamura S et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant.37(4), 425–431 (2006).
   PubMed Web of Science ®Google Scholar
• Kim HJ, Bang SM, Lee J et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant.37(9), 819–824 (2006).
   PubMed Web of Science ®Google Scholar
• Mori Y, Aoki T, Takenaka K et al. Successful treatment of refractory advanced nasal NK/T cell lymphoma with unrelated cord blood stem cell transplantation incorporating focal irradiation. Int. J. Hematol.91(1), 107–111 (2010).
   PubMed Web of Science ®Google Scholar
• Okamura T, Hatsukawa Y, Arai H, Inoue M, Kawa K. Blood stem-cell transplantation for chronic active Epstein–Barr virus with lymphoproliferation. Lancet356(9225), 223–224 (2000).
   PubMed Web of Science ®Google Scholar
• Teshima T, Miyaji R, Fukuda M, Ohshima K. Bone-marrow transplantation for Epstein–Barr-virus-associated natural killer cell-large granular lymphocyte leukaemia. Lancet347(9008), 1124 (1996).
   PubMed Web of Science ®Google Scholar
• Kawa K, Okamura T, Yasui M, Sato E, Inoue M. Allogeneic hematopoietic stem cell transplantation for Epstein–Barr virus-associated T/NK-cell lymphoproliferative disease. Crit. Rev. Oncol. Hematol.44(3), 251–257 (2002).
   PubMed Web of Science ®Google Scholar
• Okamura T, Kishimoto T, Inoue M et al. Unrelated bone marrow transplantation for Epstein–Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant.31(2), 105–111 (2003).
   PubMed Web of Science ®Google Scholar
• Murashige N, Kami M, Kishi Y et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br. J. Haematol.130(4), 561–567 (2005).
   PubMed Web of Science ®Google Scholar
• Sato E, Ohga S, Kuroda H et al. Allogeneic hematopoietic stem cell transplantation for Epstein–Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am. J. Hematol.83(9), 721–727 (2008).
   PubMed Web of Science ®Google Scholar
• Jung CK, Lee KY, Kim Y et al. Epstein–Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas. Pathol. Int.51(5), 355–363 (2001).
   PubMed Web of Science ®Google Scholar
• Lin CW, Chen YH, Chuang YC, Liu TY, Hsu SM. CD94 transcripts imply a better prognosis in nasal-type extranodal NK/T-cell lymphoma. Blood102(7), 2623–2631 (2003).
   PubMed Web of Science ®Google Scholar
• Xiang-Lan M, Zu-Lan S, Dan H, Bi-Hong S, Ya-Qin P, Han-Liang L. Skp2/p27 expression profile is correlated with Epstein–Barr virus status in extranodal nasal-type natural killer cell lymphoma. Transl. Res.151(6), 303–308 (2008).
   PubMed Web of Science ®Google Scholar
• Siu LL, Chan JK, Wong KF, Choy C, Kwong YL. Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br. J. Haematol.122(1), 70–77 (2003).
   PubMed Web of Science ®Google Scholar
• Isobe Y, Sugimoto K, Yang L et al. Epstein–Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. Cancer Res.64(6), 2167–2174 (2004).
   PubMed Web of Science ®Google Scholar
• Merlo A, Turrini R, Dolcetti R, Zanovello P, Amadori A, Rosato A. Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. Expert Opin. Biol. Ther.8(9), 1265–1294 (2008).
   PubMed Web of Science ®Google Scholar
• Perrine SP, Hermine O, Small T et al. A Phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein–Barr virus-associated lymphoid malignancies. Blood109(6), 2571–2578 (2007).
   PubMed Web of Science ®Google Scholar
• Cho HI, Hong YS, Lee MA et al. Adoptive transfer of Epstein–Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int. J. Hematol.83(1), 66–73 (2006).
   PubMed Web of Science ®Google Scholar
• Bollard CM, Gottschalk S, Leen AM et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood110(8), 2838–2845 (2007).
   PubMed Web of Science ®Google Scholar